ArticleNPJ breast cancer2019
SET
Open access · goldAbstract read
In one paragraph
Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
53.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 354 citations in OpenAlex.
- Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.Nature communications · 2026Trial
- Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer cell · 2021Trial
- Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Trial
- CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer.Research square · 2026Article
- Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer.NPJ breast cancer · 2026Article
- A PML1-CCL5-PI3K/MAPK feedback loop governs survival of endocrine-resistant breast cancer cells.Cell death and differentiation · 2026Review
- PRECOG update: an augmented resource of clinical outcome associations with gene expression for adult, pediatric, and immunotherapy cohorts.Nucleic acids research · 2026Article
- Synergistic Targeting of EGFR, ESR1, BCL2, and TP53 Pathways: A Multi-Pronged Approach for Advanced Breast Cancer Therapy.Current cancer drug targets · 2026Review
- Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.Breast cancer research and treatment · 2025Article
- Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization.Cell genomics · 2025Article
- Assessment ofHealth science reports · 2025Article
- Unexpected Expression and Function of FcεRI in Immortalized Breast Cancer Cells: A Cautionary Null Study.Cells · 2024Article
- EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology.NPJ breast cancer · 2024Article
- Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.Cancer biology & medicine · 2024Article
- Article
- Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.Clinical and translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 6 countries.
Bruno V Sinn1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.ORCID 0000-0002-1257-9799
Chunxiao Fu1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Rosanna Lau1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Jennifer Litton3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Tsung-Heng Tsai1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Rashmi Murthy3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Alda Tam4Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Eleni Andreopoulou3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Yun Gong1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Ravi Murthy4Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Rebekah Gould1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Ya Zhang1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Tari A King6Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA USA.
Agnes Viale7Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY USA.
Victor Andrade7Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY USA.
Dilip Giri7Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY USA.
Roberto SalgadoDepartment of Pathology, GZA-ZNA, Antwerp, Belgium.
Ioanna Laios11Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
Christos Sotiriou12Translational Breast Cancer Laboratory, Institut Jules Bordet, Brussels, Belgium.
Esmeralda C Marginean13Department of Pathology and Surgery, University of Ottawa, Ottawa, Canada.
Danielle N Kwiatkowski3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Rachel M Layman3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Daniel Booser3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Christos Hatzis14Department of Medicine, Yale University School of Medicine, New Haven, CT USA.
V Vicente Valero3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
W Fraser Symmans1Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
The University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USInstitut Jules Bordet · BEBrigham and Women's Hospital · USPeter MacCallum Cancer Centre · AUUniversity of Ottawa · CAYale University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MIntegrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast CancerU01CA215547 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SYMMANS, WILLIAM F · 2017 to 2021
$1.6MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA008748NCI NIH HHS U01 CA215547
Abstract
There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcriptional activity and functional mutation. We developed the SET
Indexed as
Breast cancerPredictive markers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.